SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
SCHEDULE 13D
 (Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(AMENDMENT NO. 7)(1)
CADUS PHARMACEUTICAL CORPORATION

(Name of Issuer)

COMMON STOCK, $0.01 PAR VALUE

(Title of Class of Securities)

127639102

(CUSIP Number)

Sandra Leung
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154
(212) 546-4000
 (Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

APRIL 10, 2003
 (Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box / /.
(Continued on following pages)
(Page 1 of 11)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-------------------------
CUSIP No. 127639102               SCHEDULE 13D                  Page 2 of 11
------------------------

-------------------------------------------------------------------------------
 (1) Names of Reporting Persons.
     BRISTOL-MYERS SQUIBB COMPANY

     S.S. or I.R.S. Identification Nos. of Above Persons (entities only)
     I.R.S. Employer Identification Number 22-079-0350

-------------------------------------------------------------------------------
 (2) Check the Appropriate Box if a Member of a Group*                 (a)  / /
                                                                       (b)  /X/
-------------------------------------------------------------------------------
 (3) SEC Use Only

-------------------------------------------------------------------------------
 (4) Source of Funds*
     WC
-------------------------------------------------------------------------------
 (5) Check if Disclosure of Legal Proceedings is Required Pursuant to
     Items 2(d) or 2(e)                                                    / /
-------------------------------------------------------------------------------
 (6) Citizenship or Place of Organization
     Delaware
-------------------------------------------------------------------------------
 Number of Shares             (7) Sole Voting Power
 Beneficially                        807,040
 Owned by                    --------------------------------------------------
 Each Reporting               (8) Shared Voting Power
 Person With                         0
                             --------------------------------------------------
                              (9) Sole Dispositive Power
                                     807,040
                             --------------------------------------------------
                             (10) Shared Dispositive Power
                                     0
-------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
               807,040
-------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
                                                                            / /
-------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
               6.2%
-------------------------------------------------------------------------------
(14) Type of Reporting Person*
     CO
-------------------------------------------------------------------------------	

----------------------
CUSIP No. 127639102                 SCHEDULE 13D                 Page 3 of 11
----------------------

This Amendment No. 7 is being filed to amend Item 5 of this Schedule 13D.

Item 1.  SECURITY AND ISSUER.

                  The class of equity securities to which this Statement relates
is the Common Stock, par value $0.01 per share (the "COMMON STOCK"), of Cadus
Pharmaceutical Corporation, a Delaware corporation (the "ISSUER"), which has its
principal executive offices at 767 Fifth Avenue, New York, NY 10153.

Item 2.  IDENTITY AND BACKGROUND.

                  This Amendment is being filed by Bristol-Myers Squibb Company,
a Delaware corporation (the "COMPANY"). The Company conducts its principal
business and maintains its principal office at 345 Park Avenue, New York, NY
10154. The Company is a worldwide pharmaceutical and related health care
products company.

                  The name, business address, present principal occupation or
employment and citizenship of each executive officer and director of the Company
is set forth on SCHEDULE A which is incorporated herein by reference.

                  During the past five years, neither the Company nor, to the
best knowledge of the Company, any of its executive officers or directors (i)
has been convicted in a criminal proceeding (excluding traffic violations or
similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and, as a result of such
proceeding, was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.

Item 3.  SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

                  In July 1994, the Issuer and the Company entered into a
research collaboration, whereby the Company agreed to make an initial equity
investment of $12,500,000 in the Issuer's Series B Preferred Stock. The Company
made an additional equity investment of $5,000,000 in the Issuer's Series B
Preferred Stock in September 1995 upon the Issuer achieving a research
milestone. Both equity investments came out of the working capital of the
Company.	

------------------------
CUSIP No. 127639102                    SCHEDULE 13D               Page 4 of 11
------------------------

                  On July 17, 1996, the Issuer completed an initial public
offering of its Common Stock with a per share offering price of $7.00. The
Company made an additional equity investment of $2,500,000, acquiring 355,000
shares of Common Stock. The purchase price for this investment came out of the
working capital of the Company.

Item 4.  PURPOSE OF TRANSACTION.

                  The Company acquired the Common Stock of the Issuer for the
purpose of making an investment in the Issuer and not with the view to, or for
resale in connection with, any distribution thereof. The Common Stock of the
Issuer was initially acquired in connection with a research collaboration
between the Company and the Issuer which expired in July 1999.

                  The Company and the Issuer are parties to a letter agreement
(the "LETTER AGREEMENT") concerning the Company's shares of the Common Stock.
Such Letter Agreement is filed as an exhibit hereto and is incorporated herein
by reference. The Letter Agreement includes certain notice requirements and
transfer restrictions with respect to the Company's shares of the Common Stock.
Subject to market conditions and the Letter Agreement, the Company may, in its
sole discretion, sell all or a portion of its shares of Common Stock from time
to time in open market transactions or otherwise.

Item 5.  INTEREST IN SECURITIES OF THE ISSUER.

                  To the best knowledge of the Company, as of December 31, 2002,
the Company is the beneficial owner of 807,040 shares of Common Stock of the
Issuer or approximately 6.2% of the Common Stock of the Issuer currently
outstanding. The Company has the sole power to vote and dispose of all the
shares of the Common Stock of the Issuer that it owns.

                  Except as set forth in this Item 5 and on SCHEDULE B attached
hereto which is incorporated herein by reference, neither the Company nor, to
the best knowledge of the Company, any of its officers or directors owns any
shares of Common Stock.

                  Except as set forth in Item 3 and on SCHEDULE B attached
hereto which is incorporated herein by reference, neither the Company nor, to
the best knowledge of the Company, any of its executive officers or directors
has effected any transaction in shares of Common Stock during the past sixty
(60) days.	

------------------------
CUSIP No. 127639102                    SCHEDULE 13D               Page 5 of 11
------------------------

Item 6.  CONTRACTS, ARRANGEMENTS, UNDERSTANDING OR RELATIONSHIPS WITH RESPECT
         TO SECURITIES OF THE ISSUER.

                  The Preferred Stock Purchase Agreement, together with First
Amendment thereto, filed as an exhibit hereto is incorporated herein by
reference. Except as set forth in such Agreement or the Letter Agreement,
neither the Company nor, to the best knowledge of the Company, any of its
officers or directors have entered into any contracts, arrangements,
understandings or relationships (legal or otherwise) with respect to the Common
Stock of the Issuer.

Item 7.  MATERIAL TO BE FILED AS EXHIBITS.

 1.      Preferred Stock Purchase Agreement dated as of July 26, 1994 between
         Issuer and the Company concerning Series B Preferred Stock, together
         with the First Amendment thereto dated as of October 31, 1995
         (incorporated herein by reference to Exhibit No. 10.8 to Registration
         Statement No. 333-4441 on Form S-1).

 2.      Letter Agreement dated March 23, 1999 between the Issuer and the
         Company (incorporated herein by reference to Exhibit No. 2 to Amendment
         No. 2 to this Schedule 13D).	

------------------------
CUSIP No. 127639102                    SCHEDULE 13D               Page 6 of 11
------------------------

                                    SIGNATURE

         After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Statement is true, complete and
correct.

Dated:    April 16, 2003

                                       BRISTOL-MYERS SQUIBB COMPANY

                                       By:  /s/ SANDRA LEUNG
                                            ----------------------------------
                                            Sandra Leung
                                            Corporate Secretary	

------------------------
CUSIP No. 127639102                SCHEDULE 13D                   Page 7 of 11
------------------------

                                   SCHEDULE A

                  The following information sets forth the name, citizenship,
business address and present principal occupation of each of the directors and
executive officers of the Company. Except as set forth below, each of the
directors and executive officers of the Company is a citizen of the United
States of America. Each of the Company's executive officer's business address is
345 Park Avenue, New York, New York 10154, unless otherwise indicated.

DIRECTORS OF BRISTOL-MYERS SQUIBB COMPANY

NAME AND BUSINESS ADDRESS                  PRESENT PRINCIPAL OCCUPATION
-------------------------                  -----------------------------
Peter R. Dolan                             Chairman and Chief Executive Officer
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY  10154

Robert E. Allen                            Retired Chairman and Chief Executive
AT&T Corp.                                 Officer
180 Park Avenue
Room 1E38
Florham Park, NJ  07932

Lewis B. Campbell                          Chairman, President and Chief
Textron Inc.                               Executive Officer
40 Westminster Street
Providence, RI  02903-2596

Vance D. Coffman                           Chairman and Chief Executive Officer
Lockheed Martin Corporation
6801 Rockledge Drive
Bethesda, MD  20817

Ellen V. Futter                            President
American Museum of Natural History
Central Park West at 79th Street
New York, NY  10024	

------------------------
CUSIP No. 127639102                   SCHEDULE 13D                Page 8 of 11
------------------------

NAME AND BUSINESS ADDRESS                  PRESENT PRINCIPAL OCCUPATION
-------------------------                  ----------------------------

Louis V. Gerstner, Jr.                     Retired Chairman and Chief Executive
IBM Corporation                            Officer
New Orchard Road
Armonk, NY  10504

Laurie H. Glimcher, M.D.                   Irene Heinz Given Professor of
Harvard Medical School and                 Immunology, Harvard School of Public
Harvard School of Public Health            Health and Professor of Medicine,
Dept. of Immunology and                    Harvard Medical School
Infectious Diseases
651 Huntington Avenue, FXB-2
Boston, MA  02115

Leif Johansson                             President, AB Volvo and Chief
AB Volvo                                   Executive Officer, The Volvo Group
SE-40508
Goteborg, Sweden
Citizen of Sweden

James D. Robinson III                      Chairman and Chief Executive Officer
RRE Investors
126 East 56th Street, 22nd Floor
New York, NY  10022

Louis W. Sullivan, M.D.                    President Emeritus
Morehouse School of Medicine
720 Westview Drive, S.W.
Atlanta, GA  30310-1495

EXECUTIVE OFFICERS OF BRISTOL-MYERS SQUIBB COMPANY

NAME                                       PRESENT PRINCIPAL OCCUPATION
----                                       ----------------------------

Peter R. Dolan                             Chairman and Chief Executive Officer

Lamberto Andreotti                         Senior Vice President and President,
Citizen of Italy                           International

Harrison M. Bains, Jr.                     Vice President, Tax & Treasury	

------------------------
CUSIP No. 127639102                    SCHEDULE 13D                Page 9 of 11
------------------------

NAME                                       PRESENT PRINCIPAL OCCUPATION
----                                       ----------------------------

Stephen E. Bear                            Senior Vice President, Human
                                           Resources

Andrew G. Bodnar, M.D.                     Senior Vice President, Strategy and
                                           Medical & External Affairs

Andrew R. J. Bonfield                      Senior Vice President and
Citizen of the United Kingdom              Chief Financial Officer

Wendy L. Dixon                             Chief Marketing Officer and
Citizen of the United Kingdom and          President, Global Marketing
the United States of America

Donald J. Hayden, Jr.                      Executive Vice President and
                                           President, Americas

Tamar. D. Howson                           Senior Vice President, Corporate and
                                           Business Development

Sandra Leung                               Vice President and Corporate
                                           Secretary

John L. McGoldrick                         Executive Vice President and General
                                           Counsel

Dean J. Mitchell                           President, U.S. Primary Care
Citizen of the United Kingdom

James B. D. Palmer, M.D.                   Chief Scientific Officer and
Citizen of the United Kingdom and          President, Pharmaceutical Research
the United States of America               Institute

Elliot Sigal, M.D., Ph.D.                  Senior Vice President, Global
                                           Clinical and Pharmaceutical
                                           Development

John L. Skule                              Senior Vice President, Corporate and
                                           Environmental Affairs

David L. Zabor                             Vice President and Controller	

------------------------
CUSIP No. 127639102                       SCHEDULE 13D            Page 10 of 11
------------------------

                                   SCHEDULE B

SHARES OF COMMON STOCK OWNED

         None.

TRANSACTIONS IN SHARES OF COMMON STOCK

         Sales on the open market by the Company of the Issuer's Common Stock
from the date that was 60 days prior to the date of event requiring the filing
of this Statement are described below:

            DATE                  NUMBER OF SHARES               PRICE PER SHARE
            ----                  ----------------               ---------------
          02/19/03                     2,000                          $1.11
          03/04/03                     8,000                          $1.11
          03/10/03                     3,000                          $1.13
          03/17/03                     1,500                          $1.12
          03/18/03                     8,000                          $1.10
          03/28/03                    16,960                          $1.09
          04/03/03                     6,500                          $1.17
          04/07/03                     4,000                          $1.18
          04/08/03                     6,000                          $1.20
          04/09/03                     8,000                          $1.22
          04/10/03                    12,000                          $1.26	

------------------------
CUSIP No. 127639102                  SCHEDULE 13D                Page 11 of 11
------------------------

                                  EXHIBIT INDEX

EXHIBIT
NUMBER   DOCUMENT
------   --------

 1       Preferred Stock Purchase Agreement dated as of July 26, 1994 between
         Cadus Pharmaceutical Corporation and Bristol-Myers Squibb Company,
         together with the First Amendment thereto dated as of October 31, 1995
         (incorporated herein by reference to Exhibit No. 10.8 to Registration
         Statement No. 333-4441 on Form S-1).

 2       Letter Agreement dated March 23, 1999 between the Issuer and the
         Company (incorporated herein by reference to Exhibit No. 2 to Amendment
         No. 2 to this Schedule 13D).